TG Therapeutics (TGTX) Revenue & Revenue Breakdown
TG Therapeutics Revenue Highlights
Latest Revenue (Y)
$233.66M
Latest Revenue (Q)
$73.47M
Main Segment (Y)
License Revenue
Main Geography (Y)
Worldwide
TG Therapeutics Revenue by Period
TG Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $233.66M | 8290.02% |
| 2022-12-31 | $2.79M | -58.36% |
| 2021-12-31 | $6.69M | 4300.66% |
| 2020-12-31 | $152.00K | - |
| 2019-12-31 | $152.00K | - |
| 2018-12-31 | $152.00K | -0.25% |
| 2017-12-31 | $152.38K | - |
| 2016-12-31 | $152.38K | - |
| 2015-12-31 | $152.38K | - |
| 2014-12-31 | $152.38K | - |
| 2013-12-31 | $152.38K | 699.98% |
| 2012-12-31 | $19.05K | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2007-12-31 | - | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | -100.00% |
| 2002-12-31 | $500.00K | -81.56% |
| 2001-12-31 | $2.71M | -49.39% |
| 2000-12-31 | $5.36M | 346.58% |
| 1999-12-31 | $1.20M | -60.00% |
| 1998-12-31 | $3.00M | 2900.00% |
| 1997-12-31 | $100.00K | - |
| 1996-12-31 | $100.00K | - |
TG Therapeutics generated $233.66M in revenue during NA 2023, up 8290.02% compared to the previous quarter, and up 153725.00% compared to the same period a year ago.
TG Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $73.47M | 15.74% |
| 2024-03-31 | $63.47M | 44.35% |
| 2023-12-31 | $43.97M | -73.48% |
| 2023-09-30 | $165.81M | 931.57% |
| 2023-06-30 | $16.07M | 106.00% |
| 2023-03-31 | $7.80M | 9653.75% |
| 2022-12-31 | $80.00K | -14.89% |
| 2022-09-30 | $94.00K | -84.18% |
| 2022-06-30 | $594.00K | -70.54% |
| 2022-03-31 | $2.02M | -13.14% |
| 2021-12-31 | $2.32M | 14.33% |
| 2021-09-30 | $2.03M | 31.39% |
| 2021-06-30 | $1.54M | 94.83% |
| 2021-03-31 | $793.00K | 1986.84% |
| 2020-12-31 | $38.00K | - |
| 2020-09-30 | $38.00K | - |
| 2020-06-30 | $38.00K | - |
| 2020-03-31 | $38.00K | - |
| 2019-12-31 | $38.00K | - |
| 2019-09-30 | $38.00K | - |
| 2019-06-30 | $38.00K | - |
| 2019-03-31 | $38.00K | - |
| 2018-12-31 | $38.00K | - |
| 2018-09-30 | $38.00K | - |
| 2018-06-30 | $38.00K | - |
| 2018-03-31 | $38.00K | -0.25% |
| 2017-12-31 | $38.09K | -0.00% |
| 2017-09-30 | $38.10K | 0.00% |
| 2017-06-30 | $38.09K | - |
| 2017-03-31 | $38.09K | - |
| 2016-12-31 | $38.09K | -0.00% |
| 2016-09-30 | $38.10K | 0.00% |
| 2016-06-30 | $38.09K | - |
| 2016-03-31 | $38.09K | - |
| 2015-12-31 | $38.09K | -0.00% |
| 2015-09-30 | $38.10K | 0.00% |
| 2015-06-30 | $38.09K | - |
| 2015-03-31 | $38.09K | - |
| 2014-12-31 | $38.09K | -0.00% |
| 2014-09-30 | $38.10K | 0.00% |
| 2014-06-30 | $38.09K | - |
| 2014-03-31 | $38.09K | - |
| 2013-12-31 | $38.09K | -0.00% |
| 2013-09-30 | $38.10K | 0.00% |
| 2013-06-30 | $38.09K | - |
| 2013-03-31 | $38.09K | 99.99% |
| 2012-12-31 | $19.05K | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | 100.00% |
| 2007-09-30 | - | - |
TG Therapeutics generated $73.47M in revenue during Q2 2024, up 15.74% compared to the previous quarter, and up 941.51% compared to the same period a year ago.
TG Therapeutics Revenue Breakdown
TG Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Product | $92.00M | - | - |
| Other Revenue | $1.50M | - | - |
| License Revenue | $140.15M | - | - |
| License revenue | - | $152.00K | $152.00K |
| Product revenue, net | - | $2.63M | $6.54M |
TG Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License Revenue (59.98%), Product (39.38%), and Other Revenue (0.64%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Revenue | $415.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| License Revenue | $38.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty | $33.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $50.49M | $66.94M | $25.07M | $1.51M | $755.00K | - | - | - | - | - | - | - | - |
| Milestone | $12.50M | - | - | - | - | - | - | - | - | - | - | - | - |
| License | - | - | $140.75M | $38.00K | $38.00K | - | - | - | - | - | - | - | - |
| License revenue | - | - | - | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | $38.00K | - | - |
| Product revenue, net | - | - | - | $16.04M | $7.76M | $42.00K | $56.00K | $556.00K | $1.98M | $2.28M | $1.99M | - | - |
TG Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (79.54%), Milestone (19.69%), Other Revenue (0.65%), License Revenue (0.06%), and Royalty (0.05%).
TG Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 |
|---|---|
| International | $3.22M |
| Worldwide | $92.00M |
TG Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: Worldwide (96.62%), and International (3.38%).
TG Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EXEL | Exelixis | $1.83B | $637.18M |
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| BTAI | BioXcel Therapeutics | $1.38M | $1.10M |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| VKTX | Viking Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
TGTX Revenue FAQ
What is TG Therapeutics’s yearly revenue?
TG Therapeutics's yearly revenue for 2023 was $233.66M, representing an increase of 8290.02% compared to 2022. The company's yearly revenue for 2022 was $2.78M, representing a decrease of -58.36% compared to 2021. TGTX's yearly revenue for 2021 was $6.69M, representing an increase of 4300.66% compared to 2020.
What is TG Therapeutics’s quarterly revenue?
TG Therapeutics's quarterly revenue for Q2 2024 was $73.47M, a 15.74% increase from the previous quarter (Q1 2024), and a 357.05% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $63.47M, a 44.35% increase from the previous quarter (Q4 2023), and a 713.46% increase year-over-year (Q1 2023). TGTX's quarterly revenue for Q4 2023 was $43.97M, a -73.48% decrease from the previous quarter (Q3 2023), and a 54863.75% increase year-over-year (Q4 2022).
What is TG Therapeutics’s revenue growth rate?
TG Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 3393.23%, and for the last 5 years (2019-2023) was 153625.00%.
What are TG Therapeutics’s revenue streams?
TG Therapeutics's revenue streams in c 23 are Product, Other Revenue, and License Revenue. Product generated $92M in revenue, accounting 39.38% of the company's total revenue Other Revenue generated $1.5M in revenue, accounting 0.64% of the company's total revenue License Revenue generated $140.15M in revenue, accounting 59.98% of the company's total revenue
What is TG Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of TG Therapeutics was License Revenue. This segment made a revenue of $140.15M, representing 59.98% of the company's total revenue.